Hearing Evaluations in Children With Retinoblastoma Treated With Intra-arterial Carboplatin Chemotherapy: A Single Institution Review.

Mary Elizabeth Davis,Edith Guarini,Kerri O'Connor,Jasmine H Francis,David H Abramson
{"title":"Hearing Evaluations in Children With Retinoblastoma Treated With Intra-arterial Carboplatin Chemotherapy: A Single Institution Review.","authors":"Mary Elizabeth Davis,Edith Guarini,Kerri O'Connor,Jasmine H Francis,David H Abramson","doi":"10.3928/01913913-20240807-02","DOIUrl":null,"url":null,"abstract":"PURPOSE\r\nTo determine whether the administration of intra-arterial carboplatin affected the hearing of children with retinoblastoma.\r\n\r\nMETHODS\r\nChildren with retinoblastoma who were treated with intra-arterial carboplatin chemotherapy were included. Hearing tests before chemotherapy including tympanometry, distortion product otoacoustic emissions, and audiogram (if achievable) were performed and repeated 3 to 9 months after concluding intra-arterial therapy. The study was approved by the institutional review board. Patients were identified from the retinoblastoma clinic when the treatment plan included intra-arterial carboplatin chemotherapy. Children were excluded if they had previous intra-arterial carboplatin or preexisting hearing loss but were included if they had systemic carboplatin and dosing was available. Tympanometry was performed to rule out inner ear fluid. All examinations were performed by a certified audiologist with the same equipment, calibrated regularly by a certified technician.\r\n\r\nRESULTS\r\nTwenty-two children (32 eyes) were evaluable. Because most children are diagnosed at a young age and are unable to participate in an audiogram, distortion product otoacoustic emission measurement was the primary measurement. No child displayed hearing loss.\r\n\r\nCONCLUSIONS\r\nIntra-arterial chemotherapy with carboplatin did not cause ototoxicity in any child by distortion product otoacoustic emission measurement in contrast to systemic chemotherapy where ototoxicity is common. Distortion product otoacoustic emission levels were essentially unchanged from before to after intra-arterial chemotherapy in children with retinoblastoma. These findings suggest that intra-arterial carboplatin does not affect outer hair cell function, and distortion product otoacoustic emission tests can provide useful information when monitoring children at risk of developing carboplatin ototoxicity. [J Pediatr Ophthalmol Strabismus. 20XX;X(X):XXX-XXX.].","PeriodicalId":519537,"journal":{"name":"Journal of Pediatric Ophthalmology and Strabismus","volume":"59 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Ophthalmology and Strabismus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3928/01913913-20240807-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

PURPOSE To determine whether the administration of intra-arterial carboplatin affected the hearing of children with retinoblastoma. METHODS Children with retinoblastoma who were treated with intra-arterial carboplatin chemotherapy were included. Hearing tests before chemotherapy including tympanometry, distortion product otoacoustic emissions, and audiogram (if achievable) were performed and repeated 3 to 9 months after concluding intra-arterial therapy. The study was approved by the institutional review board. Patients were identified from the retinoblastoma clinic when the treatment plan included intra-arterial carboplatin chemotherapy. Children were excluded if they had previous intra-arterial carboplatin or preexisting hearing loss but were included if they had systemic carboplatin and dosing was available. Tympanometry was performed to rule out inner ear fluid. All examinations were performed by a certified audiologist with the same equipment, calibrated regularly by a certified technician. RESULTS Twenty-two children (32 eyes) were evaluable. Because most children are diagnosed at a young age and are unable to participate in an audiogram, distortion product otoacoustic emission measurement was the primary measurement. No child displayed hearing loss. CONCLUSIONS Intra-arterial chemotherapy with carboplatin did not cause ototoxicity in any child by distortion product otoacoustic emission measurement in contrast to systemic chemotherapy where ototoxicity is common. Distortion product otoacoustic emission levels were essentially unchanged from before to after intra-arterial chemotherapy in children with retinoblastoma. These findings suggest that intra-arterial carboplatin does not affect outer hair cell function, and distortion product otoacoustic emission tests can provide useful information when monitoring children at risk of developing carboplatin ototoxicity. [J Pediatr Ophthalmol Strabismus. 20XX;X(X):XXX-XXX.].
接受动脉内卡铂化疗的视网膜母细胞瘤患儿的听力评估:单个机构回顾。
目的确定动脉内卡铂治疗是否会影响视网膜母细胞瘤患儿的听力。方法纳入接受动脉内卡铂化疗的视网膜母细胞瘤患儿。化疗前进行听力测试,包括鼓室测量、畸变产物耳声发射和听力图(如可实现),并在动脉内治疗结束后 3 至 9 个月进行重复测试。该研究获得了机构审查委员会的批准。当治疗计划包括动脉内卡铂化疗时,患者从视网膜母细胞瘤门诊中确定。曾接受过动脉内卡铂化疗或已存在听力损失的患儿不在研究范围内,但曾接受过全身卡铂化疗且可提供剂量的患儿可纳入研究范围。进行鼓室测量以排除内耳积液。所有检查均由经认证的听力学家使用相同的设备进行,并由经认证的技术人员定期校准。由于大多数儿童在确诊时年龄较小,无法参与听力检查,因此畸变产物耳声发射测量是主要的测量方法。结论通过畸变积声发射测量,卡铂的动脉外化疗未对任何儿童造成耳毒性,而全身化疗则常见耳毒性。视网膜母细胞瘤患儿动脉内化疗前后的失真积声发射水平基本保持不变。这些研究结果表明,动脉内卡铂不会影响外毛细胞的功能,畸变积声发射测试可为监测有卡铂耳毒性风险的儿童提供有用的信息。[20XX;X(X):XXX-XXX.].
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信